ADXN — Addex Therapeutics Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1574232 ·
Last close
$6.21
Market Cap
$7.86M
52W High
$7.60
52W Low
$5.41
ADV30
3,677
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 248 | — | -779,263 | -1,836,987 | 6,364,272 | 1,638,612 | 1,597,580 |
| Sep 2025 | 29,724 | — | -696,175 | -1,577,231 | 7,330,802 | 2,187,202 | 1,372,247 |
| Jun 2025 | 0 | — | -732,898 | -1,841,165 | 8,506,015 | 2,300,994 | 1,293,289 |
| Mar 2025 | 0 | — | -606,262 | -1,472,863 | 9,484,654 | 2,825,484 | 1,188,976 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,575,307
Investing CF
$38,329
Financing CF
$1,106,473
CapEx
—
Dividends Paid
$0
Buybacks
$-2,746
EPS Diluted TTM
$-7.20
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-358,253,714
Inventory
—
Receivables
$51,247
ST Investments
$6,860
EBIT TTM
$-6,195,502
Pretax Income TTM
$-6,198,837
Interest Exp TTM
$3,335
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$172,860
EBITDA
$-2,814,174
Free Cash Flow
$-1,267,405
Enterprise Value
$6,046,372
Total Cash
$1,638,612
Total Debt
$34,688
Shares Out
1,265,844
Trailing EPS
$-9.07
Book Value
$4.81
ROE
-94.7%
ROA
-20.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 29,972 | -2,814,598 | -6,728,246 | 6,364,272 | 1,597,580 | — | -2,171,117 |
| Dec 2024 | 404,102 | -2,755,233 | 7,055,787 | 10,678,303 | 1,001,032 | — | -5,373,554 |
| Dec 2023 | 1,612,953 | -2,242,967 | -10,556,227 | 4,641,885 | 3,496,420 | — | -7,992,411 |
| Dec 2022 | 1,422,438 | -10,540,901 | -20,804,213 | 8,282,050 | 3,369,139 | — | -16,437,185 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.05
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BETRF | BetterLife Pharma Inc. | $7.85M | $0.05 | — |
| HCWB | HCW Biologics Inc. | $7.88M | $1.10 | — |
| IMNN | Imunon, Inc. | $7.82M | $1.86 | — |
| NXTC | NextCure, Inc. | $7.95M | $2.20 | — |
| NCNA | NuCana plc | $7.74M | $1.86 | — |
News headlines (Yahoo Finance, 1h cache)
Addex Convenes Annual General Meeting 2026
2026-06-05 05:00 · Yahoo
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
2026-04-30 05:00 · Yahoo
Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model
2026-04-29 05:00 · Yahoo
Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026
2026-04-23 05:00 · Yahoo
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model
2026-04-21 05:00 · Yahoo
Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment
2026-02-03 06:00 · Yahoo
Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia
2026-01-07 06:00 · Yahoo
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
2025-12-11 06:00 · Yahoo
Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Highlights: Strategic Advances Amidst ...
2025-12-04 23:06 · Yahoo
Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update
2025-12-04 06:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.